NCT01599884

N-Acetylcysteine for Patients With COPD and ChronicBronchitis

Effects of High-Dose N-Acetylcysteine on Respiratory Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis: A Randomized, Placebo-Controlled Trial-1

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 65 (estimated)
• Sponsor: Center for Veterans Research and Education · Academic / Other
• Sex: All
• Age: 40 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

N-acetylcysteine (NAC) is described as having mucolytic and antioxidant properties. It is widely prescribed for patients with chronic obstructive pulmonary disease (COPD), particularly for those who have accompanying symptoms of chronic cough and sputum production. Randomized, placebo controlled indicate that it is safe and that it may have some clinical benefit when used at relatively low doses. It is postulated that substantially higher doses of NAC will be well-tolerated and will provide better symptom control while also decreasing blood makers of oxidant stress and inflammation.

Conditions

• Chronic Obstructive Pulmonary Disease
• Chronic Bronchitis

Interventions

Type	Name	Description
DRUG	N-acetylcysteine	1800 mg twice daily for 8 weeks
DRUG	Oral acetylcysteine	Identical placebo pills twice daily for 8 weeks

Timeline

• Start date: 2012-06-01
• Primary completion: 2013-05-01
• Completion: 2013-08-01
• First posted: 2012-05-16
• Last updated: 2012-05-16

Locations

1 site across 1 country: United States